Business
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK,
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summerQuarter-end cash balance of $131 million, with no debtReaffirming all financial guidance metricsDUBLIN, May 8, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025.\n\n \n \n \n \n \n \n\n \n\"As we begin the year, we remain focused on delivering against our operational priorities for YUPELRI and ampreloxetine,\" said Rick E Winningham, CEO of Theravance Biopharma. \"Our commercial partnership with Viatris delivered solid YUPELRI sales growth, aided by a strong performance in the hospital setting. TRELEGY delivered another excellent quarter and our clinical team advanced CYPRESS enrollment, which is now nearing completion. Our interactions with the MSA community continue to highlight the urgent need for new treatments for symptomatic nOH and ampreloxetine's potentially significant value to patients, caregivers and providers, underpinning our motivation to complete CYPRESS enrollment and share our results.\"\nFirst Quarter Operational Highlights\nYUPELRI® (revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD):\nAchieved total US net sales of $58.3 million in Q1 2025, increasing 6% year-over-year (Q1 2025 vs Q1 2024).1Grew customer demand 5% for the quarter (Q1 2025 vs Q1 2024).3Increased doses pulled through the hospital channel by 48% year-over-year (Q1 2025 vs Q1 2024), reflecting another quarter of strong momentum.4Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA):\nCYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summer; top-line data anticipated ~6 months later.In April, presented data at American Acade...